1. Home
  2. ESEA vs STTK Comparison

ESEA vs STTK Comparison

Compare ESEA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

N/A

Current Price

$73.41

Market Cap

557.0M

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$5.68

Market Cap

652.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESEA
STTK
Founded
2005
2016
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.0M
652.4M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
ESEA
STTK
Price
$73.41
$5.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
★ $90.00
$15.22
AVG Volume (30 Days)
26.4K
★ 1.2M
Earning Date
11-17-2026
11-05-2026
Dividend Yield
★ 4.36%
N/A
EPS Growth
N/A
★ 53.02
EPS
★ N/A
N/A
Revenue
N/A
★ $1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
$3.39
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$51.00
$1.70
52 Week High
$79.67
$8.33

Technical Indicators

Market Signals
Indicator
ESEA
STTK
Relative Strength Index (RSI) 47.75 35.95
Support Level $71.76 $3.55
Resistance Level $74.76 $7.66
Average True Range (ATR) 1.94 0.46
MACD 0.16 -0.05
Stochastic Oscillator 42.14 12.60

Price Performance

Historical Comparison
ESEA
STTK

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: